Novartis Wins UK Court Battle Over Entresto Patent
Novartis said London’s High Court rejected Accord Healthcare’s challenge to invalidate Novartis’ Entresto patent and supplementary protection certificate, finding the planned generic would infringe. Accord, a unit of Intas Pharmaceuticals, had planned a later 2026 launch. Entresto contributes about 10% of Novartis sales. Similar results occurred in the Netherlands, while Novartis lost a US bid last year.
How this was made
The 30-second read
Why it matters
By upholding the patent and supplementary protection certificate and ruling infringement, the decision lowers the probability of near-term UK generic competition for Entresto.
Market read
This is a concrete UK legal enforcement win that should reduce UK generic-entry risk for Entresto, a meaningful revenue contributor for Novartis.
What to watch
The article does not provide dates for appeal, remaining claim scope, or how the US loss last year affects overall enforceability, so traders should avoid assuming a full global block.
Background
Novartis is defending Entresto patent validity in multiple jurisdictions; the UK case was brought by Accord Healthcare (unit of Intas Pharmaceuticals) seeking to launch a generic.
Ticker impact
UK High Court rejected a challenge to invalidate Novartis’ Entresto patent, upholding the patent and finding Accord’s generic would infringe.
Moderately positive bias for NVS as UK generic threat is pushed out, though broader impact depends on remaining jurisdictions and timelines.
The article is a direct, jurisdiction-specific legal outcome that strengthens enforceability of Entresto IP and explicitly blocks the planned generic launch in the UK.
Market effects
Reinforces the value of patent estates and supplementary protection certificates for branded pharma, potentially supporting sentiment toward IP-protected drug franchises.
UK court outcome can shift expectations for generic timelines and litigation risk premia in the UK market.
Adds to a multi-jurisdiction enforcement narrative, aligning with similar Netherlands validity findings mentioned in the article.
Counterpoint
A single UK ruling may have limited earnings impact if other jurisdictions (or appeals) still determine the ultimate generic launch timeline.
Key entities
- companyNovartis
Branded drug maker defending Entresto patent validity in the UK.
- companyAccord Healthcare
Challenger seeking to introduce a generic Entresto later this year.
- companyIntas Pharmaceuticals
Parent of Accord Healthcare, referenced as the unit behind the challenge.
- productEntresto
Blockbuster heart drug protected by the disputed patent.
- courtLondon High Court
Rejected the challenge and upheld the patent and supplementary protection certificate.
